INTRODUCTION
Tuberculosis remains one of the biggest killers among human diseases and its effective treatment by antibiotics is far from complete (Barry, 2014; Crubézy et al., 1998; Lee et al., 2014; WHO, 2012; Wirth et al., 2008) . Rifamycin and its derivatives are the most potent antibiotics used against Mycobacterium tuberculosis (causative organism for tuberculosis) (Floss & Yu, 2005; Sensi, 1983; Sensi et al., 1959 Sensi et al., , 1959 Sensi et al., -1960 Tupin et al., 2010) . The success of rifamycin is due to its exclusivity as it targets only the b-subunit of bacterial RNA polymerase (RNAP) without any effect on the same enzyme from the human host (Hartmann et al., 1967) . The antibiotic either sterically blocks the path of elongating transcript in RNAP beyond 2-3 nt (Campbell et al., 2001; Feklistov et al., 2008) or allosterically reduces the affinity of Mg 2+ ions to the active site and thereby prevents the process of transcription (Artsimovitch et al., 2005) .
The bacterial RNAP (Burgess, 1969; Chamberlin & Berg, 1962; Losick & Chamberlin, 1977; Murakami, 2013; Travers & Burgess, 1969; Vassylyev et al., 2002; Zhang et al., 1999 ) is composed of five core subunits (a 2 bb9v). Various sigma factors (s) bind and direct RNAP to specific promoters. Transcription initiation is a multistep process and involves the formation of an RNAP-promoter closed complex (RPc). After isomerization this complex converts to RNAPpromoter open complex (RPo) and initiates the process of transcription (Borukhov & Nudler, 2008; Darst, 2001; Gross et al., 1992; Gruber & Gross, 2003; Kontur et al., 2010; Mathew & Chatterji, 2006; Saecker et al., 2011) . The process of transcription initiation is modulated by various transcription activators, repressors and small regulatory molecules to fine tune the process of gene expression (Browning & Busby, 2004; Haugen et al., 2008; Nudler, 2009; Ross et al., 2013) .
Most of the rifampicin-resistant M. tuberculosis strains carry mutation(s) in the b-subunit of RNAP (Jin & Gross, 1988; Miller et al., 1994) . However, one cannot completely rule out protein-protein interactions involving RNAP as an additional mechanism towards acquisition of antibiotic tolerance (Flåtten et al., 2009; Mukherjee & Chatterji, 2008; Wegrzyn et al., 1998; Weiss et al., 2012) .
RNAP binding protein RbpA was first discovered in Streptomyces coelicolor, where it was shown to confer basal levels of rifampicin resistance and stimulated transcription both in vivo and in vitro (Newell et al., 2006; Paget et al., 2001) .When a null mutant of rbpA in S. coelicolor was transformed with rbpA from M. tuberculosis (Rv2050), tolerance to rifampicin increased~2.6-fold. A homologue of MtbRbpA was identified in Mycobacterium smegmatis as the product of the gene MSMEG_3858 (MsRbpA). MsRbpA has been shown to interact with the b-subunit of RNAP and elicit rifampicin tolerance both in vitro and in vivo (Dey et al., 2010) . It was also shown that rifampicin is released from its binding site from the RNAP-rifampicin complex in the presence of MsRbpA. Cross-linking MsRbpA and RNAP, and subsequent MS analyses, revealed that Lys 73 of a 16 aa peptide fragment of MsRbpA was cross-linked with Arg 381 of the b-subunit of RNAP. The binding site of MsRbpA on RNAP was shown to be at the interface between the b-and b9-subunits close to the rifampicin binding site, which in turn is close to the active site of RNAP (Dey et al., 2011) .
In our previous work with MsRbpA, we noticed that MsRbpA can rescue transcription inhibition in the presence of rifampicin in both the single and the multiple round transcription assays (Dey et al., 2011) . In a separate study, RbpA from M. tuberculosis (MtbRbpA) was shown to be a transcription activator at s A -dependent promoters. MtbRbpA stimulates the formation of stable RNAPpromoter complex and binds the sandwich barrel hybrid motif of the b-subunit, which is at a different location from that of M. smegmatis (Hu et al., 2012) . NMR of MtbRbpA revealed that it has a central ordered region and both N-and C-terminal ends are involved in the interaction with domain 2 of s B (Bortoluzzi et al., 2013) . It was proposed that dimeric MtbRbpA interacts with the s factor. Dimerization of RbpA for s interaction is a common theme for both M. tuberculosis and S. coelicolor (Bortoluzzi et al., 2013; Tabib-Salazar et al., 2013) . It has been shown that RbpA is an essential protein in M. tuberculosis (Forti et al., 2011) , although it is dispensable in S. coelicolor (Newell et al., 2006) .
In this report we further explore the mechanistic detail of MsRbpA functions. We show that MsRbpA activates transcription by both enhancing formation of the closed complex and increasing the rate constant of stable RNAPpromoter interaction. We further show that a 16 aa fragment from Asn 58 to Lys 73, which lies in the central region of MsRbpA and interacts with b-subunit of RNAP, is required for the transcriptional activation as well as for the transcriptional rescue by MsRbpA. Through surface plasmon resonance (SPR) studies, we have shown here that deleted MsRbpA (MsRbpA D58--73 ) binds core RNAP with 1000-fold less affinity. By contrast, it retains its interaction with s A similar to that of wild-type MsRbpA. We performed alanine scanning of this region of MsRbpA and identified the functional residues needed for transcriptional activation as well as transcription rescue in the presence of rifampicin. Furthermore, we show that MsRbpA is an essential protein for the survival of M. smegamtis.
METHODS
Bacterial strains, plasmids and growth conditions. Escherichia coli strain DH5a was used for cloning experiments. Protein expression and purification experiments were carried out using E. coli strain BL21(DE3) in Luria-Bertani (LB) medium. M. smegmatis strain mc 2 155 and M. smegmatis SM07 (used for RNAP purification) were cultured in Middlebrook 7H9 medium (Difco) containing 0.05 % Tween 80 (Sigma) and 2 % glucose with shaking, at 37 uC. Antibiotics were added to the following concentration whenever required: ampicillin, 50 mg ml 21 ; kanamycin, 50 mg ml 21 ; streptomycin, 20 mg ml 21 ; and hygromycin, 150 mg ml 21 (E. coli) or 50 mg ml
21
(M. smegmatis).
Construction of pETMsRbpA D58-73 and alanine substitution mutants of MsRbpA. The pETMsRbpA (Dey et al., 2010) Protein expression and purification. RNAP having C-terminal hexa-histidine tag in the b9-subunit was purified from M. smegmatis SMO7 after enrichment with s A (Fig. S1 ) as described previously Mukherjee & Chatterji, 2008) . MsRbpA, its alanine substitution mutants and MtbRbpA were purified as described by Dey et al. (2010) . MsRbpA D58-73 was purified from inclusion bodies according to Gentry & Burgess (1990) . Briefly, after cell lysis, the pellet was extracted with extraction buffer [50 mM Tris/HCl (pH 7.9), 200 mM KCl, 10 % glycerol, 10 mM MgCl 2 , 1 mM EDTA, 10 mM DTT and 6 M urea] at 4 uC in a stirrer for 2 h, centrifuged at 14 000 r.p.m. and the supernatant was dialysed in a renaturation buffer [50 mM Tris/HCl (pH 7.9), 200 mM KCl, 10 % glycerol, 10 mM MgCl 2 , 1 mM EDTA and 10 mM DTT] twice in 500 ml each for 6 h. The dialysed fraction was further purified through Ni-affinity chromatography. The factor s A was purified from the E. coli overexpressing strain BL21(DE3) housing pARC8171, as described by Dey et al. (2010) .
Electrophoretic mobility shift assay (EMSA). RNAP-promoter closed complex (RPc) and heparin-resistant stable RNAP-promoter (RP) were formed as described by using M. smegmatis holo RNAP and s A -dependent promoter P rrnAPCL1 . Promoter P rrnAPCL1 was chosen as it is the major rrnA promoter in several species of mycobacteria, its transcription start site has been mapped, 210 and 235 region sequences have been defined and it shows in vivo activity in exponentially growing cells (Brunner & Bujard, 1987; Stadthagen-Gomez et al., 2008) . Synthetic oligonucleotides (Sigma) containing promoter P rrnAPCL1 sequences of 94 nt (bases 275 to +19) were 59-end labelled with P-c-[ATP] (Perkin Elmer) using T4 polynucleotide kinase (NEB), annealed with a twofold molar excess of complementary strand, purified and used for EMSA. The RNAP-promoter complexes were analysed by using 4 % native PAGE. The electrophoresis was carried out at 4 uC for RPc and at room temperature for heparin-resistant RP formation. For RPc assay, RNAP (100 nM) and MsRbpA (0.05-0.5 mM) were incubated on ice for 10 min in transcription buffer [50 mM Tris/HCl (pH 7.9), 5 mM Mg-acetate, 50 mM KCl, 0.1 mM DTT, 5 % glycerol and 50 mg BSA ml
], 1 nM of labelled P rrnAPCL1 was added and incubated for another 10 min, mixed with loading dye (0.25 % bromophenol blue, 0.25 % xylene cyanol, 30 % glycerol) and loaded on 4 % native PAGE and analysed using a phosphorimager. For RP assay, 100 nM of RNAP and 0.5 mM of MsRbpA were incubated at 37 uC in transcription buffer for 10 min. To this, 1 nM of end-labelled P rrnAPCL1 was added and incubated at 37 uC. Samples were taken out at indicated time intervals, mixed with 50 mg heparin ml 21 and loading dye and loaded on 4 % native PAGE. DNA-protein complexes were separated by PAGE from the free DNA and analysed using a phosphorimager (FLA2000; Fujifilm). The gel bands were quantified by Multi Gauge software version 2.3 (Fujifilm). Oligonucleotides used in EMSA studies are listed in Table S1 .
Promoter-specific single and multiple round gel-based transcription assays. For in vitro single and multiple round transcription assays, P rrnAPCL1 was PCR amplified using primers P rrnAPCL1 For and P rrnAPCL1 Rev from the plasmid pUC18-rrnA. The promoter sequence is included within nucleotides 269 to +120. For single round transcription, 100 nM RNAP was incubated with or without rifampicin (10 mM) for 5 min at 37 uC, and MsRbpA was added and incubated for 10 min. Subsequently, 10 nM P rrnAPCL1 promoter was added and further incubated for 10 min. ), precipitated by adding a 0.1 volume of 3 M Na-acetate and 2.5 volume of ethanol. This mixture was incubated at 280 uC for 10 min, centrifuged at 14 000 r.p.m. and the supernatant was discarded. The pellet was dried and mixed with formamide dye [80 % (v/v) formamide, 8 % glycerol, 8 mM 0.01 % bromophenol blue, 0.01 % xylene cyanol] and loaded on 10 % denaturing urea-PAGE, and analysed using a phosphorimager (FLA2000). For multiple round transcription, 50 nM RNAP and 5 nM promoter were used; heparin was not added in the reaction. Other conditions were as for single round transcription. To prevent any contaminating RNase activity in the single and multiple round run-off transcription reaction, Murine RNase Inhibitor (New England Biolabs) was used. All the primers and plasmids used are listed in Tables S1 and S2, respectively.
Surface plasmon resonance (SPR) studies. All SPR experiments were carried out with Biacore 3000 instruments at 25 uC using a research grade CM5 sensor chip (GE Healthcare Bio-Sciences). All buffer solutions were freshly prepared, passed through a 0.22 mm pore-size filter and degassed. MsRbpA and MsRbpA D58-73 were immobilized on the CM5 sensor chip through amine coupling chemistry according to the manufacturer's protocol. Briefly, the chip surface was activated by injecting 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide/N-hydroxysuccinimide (EDC/NHS) at a flow rate of 5 ml min 21 for 10 min. MsRbpA and MsRbpA D58-73 in sodium acetate buffer (pH 4.0) were injected at a flow rate of 5 ml min
(for 5 min), and finally 1 M ethanolamine-HCl (pH 8.5) was injected at a flow rate of 5 ml min 21 (for 5 min) to deactivate excess reactive groups. A control (blank) channel was prepared by activation with EDC/NHS and then treated with ethanolamine. Core RNAP and s A were passed through the chip in running buffer [10 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM EDTA]. The flow rate for analyses was kept at 10 ml min
, and the association and dissociation times were kept at 100 s. After every injection, the sensor chip surface was regenerated by injection of 2-10 ml of 0.01-0.04 % SDS at a flow rate of 100 ml min 21 , which was followed by washing with running buffer until the baseline returned to zero. All the response units thus obtained during analyses are corrected with that of the blank channel. All data were analysed by fitting both the association and the dissociation phases for various concentrations through BIAevaluation software version 4.1.
Construction of conditional mutants of MsRbpA in M. smegmatis. The methodology for making conditional mutants of MsRbpA in M. smegmatis was adapted from that of Boldrin et al. (2010) . To generate conditional knockdown of MsRbpA, the first 336 bp of the 59 end fragment of msRbpA (MSMEG_3858) was cloned downstream of Pristinomycin I repressor-dependent promoter (P ptr ) between sites NsiI and XhoI using the primer PrbpF(NsiI) and PrbpR(XhoI) in a suicide vector pFRA50 to form pFRA50RbpA. This construct was electroporated in M. smegmatis mc 2 155. After homologous recombination, an intact copy of endogenous msRbpA comes under the control of P ptr , leaving behind a non-functional msRbpA fragment within its native promoter (Fig. S2a ). This strain was named MS 28, it was confirmed using PCR with two sets of primers RP707F, PptrF and PrbpR (XhoI) (Fig. S2b, c) . A second plasmid pFRA42A carrying the genes for two repressors, tetracycline repressor (TetR) and Pristinomycin I repressor (Pip), was then electroporated into strain MS 28. This plasmid recombines at the site attB in the bacterial chromosome to generate strain MS 101. TetR is under a constitutive promoter whereas Pip is under control of the TetR repressible promoter. pFRA42A also harbours the lacZ gene. Successful recombinants were screened on plates containing X-Gal, streptomycin and hygromycin. The level of repression of MsRbpA was checked by adding anhydrotetracycline (ATc) at 100-800 ng ml
.
RESULTS

MsRbpA enhances the formation of RPc
The initiation of transcription begins with the sequencespecific binding of holo RNAP to promoters to form RPc (Buc & McClure, 1985; McClure, 1985) . To explore the role of MsRbpA at this step of transcription, RPc was formed by incubating a fixed concentration of RNAP (100 nM) and end-labelled P rrnAPCL1 (1 nM). The specificity of RPc formation was determined by challenging the complex formed with specific DNA (unlabelled P rrnAPCL1 promoter) and a non-specific DNA. When the complex formed was challenged with higher concentrations of unlabelled promoter DNA, the complex disappeared, suggesting the specificity of the binding reaction. However, when challenged with a non-specific DNA, no effect on the complex formation was detected (Fig. S3 ). This experiment establishes that the RPc formed was indeed specific and reversible and not a non-specific interaction between RNAP and promoter. To decipher the role of MsRbpA in RPc formation, reactions were carried out on ice in the absence as well as in the presence of increasing concentrations of MsRbpA to form RPc. In Fig. 1(a) , lane 1 is a control, where only the end-labelled promoter is present. Similarly, in Fig. 1(a) , lane 3 shows DNA in the absence of RNAP but in the presence of MsRbpA. In Fig. 1(a) , lane 2 depicts the formation of the RPc in the absence of MsRbpA, whereas in Fig. 1(a) , lanes 4-8 show increasing levels of RPc formation concomitant with increases in MsRbpA concentrations. In the presence of 0.5 mM MsRbpA, the amount of RPc increased 1.6-fold in comparison with that in the absence of the protein (Fig. 1b) , suggesting MsRbpA favours the formation of RPc.
MsRbpA increases the rate constant (k2) of stable RNAP-promoter complex formation RPc isomerizes to transcriptionally competent RPo through several intermediate complexes, in which an~13 bp DNA fragment around the start site melts to forms the transcription bubble and the initiation of transcription event occurs. One of the important steps that lead to the formation of RPo is the generation of stable RP, which is heparin resistant and stable. We followed the influence of MsRbpA in the process of conversion from RPc to RP. RP was formed with 100 nM RNAP and labelled P rrnAPCL1 (1 nM) at 37 u C in the presence or absence of MsRbpA (0.5 mM). The fraction of bound complex (F t ) at various time points was calculated after normalizing the same with the value obtained at the maximum incubation time. The pseudo-first-order rate constant (k 2 ) was calculated from the equation [2ln (12F t )5k 2 t], where F t is equivalent to (12P t /P 0 ); P 0 and P t are the amount of bound DNA at time '0' and 't', respectively Jia & Patel, 1997; Lutz et al., 2001; Tsujikawa et al., 2002) . In the presence of MsRbpA, k 2 increases 2.7-fold in comparison with that of in the absence of MsRbpA (Fig. 2) .
Are the activation of transcription by MsRbpA and rescue of transcription inhibition two sides of the same coin?
In a previous study, we reported that at the P rel promoter, MsRbpA is able to rescue transcription inhibition by rifampicin (Dey et al., 2011) . MtbRbpA, by contrast, can activate transcription (Hu et al., 2012) . To investigate if
MsRbpA can carry out both the above functions, we performed single and multiple round transcriptions. In Fig.  3(a) , lanes 3-5 show activation of single round transcription at P rrnAPCL1 as a function of increasing concentrations of MsRbpA. Note that rifampicin was not present in Fig.  3(a) , lanes 3-5. Interestingly, transcription was completely inhibited in the presence of rifampicin [ Fig. 3(a) , lane 2]. However, transcripts reappeared when MsRbpA was added to the reaction [ Fig. 3(a) , lanes 6-8]. Fig. 3(b) depicts the variation in transcription output as a function of MsRbpA with error limits. If we reverse the order of addition of rifampicin and MsRbpA in a single round transcription, we still observe the transcription rescue by MsRbpA (Fig. S4) .
One can argue that the rescue effect presented here is due to the residual RNA synthesis activated by MsRbpA. However, rifampicin is a potent inhibitor of transcription (Campbell ). Any transcript formation beyond 2-3 nt in the presence of rifampicin necessitates removal of the inhibitor as RNA synthesis cannot proceed in the presence of rifampicin. We believe that MsRbpA rescues rifampicin-induced inhibition by completely removing it (Dey et al., 2011) . We observed rescue of rifampicin-induced transcription inhibition in the presence of MsRbpA in multiple round transcription as well (Fig. 3c) . In Fig. 3(c) , lanes 1-4 represent time-dependent multiple round transcription at promoter P rrnAPCL1 , which was inhibited in the presence of rifampicin when added after the 59 of the start of the transcription reaction [ Fig. 3(c) , lanes 9-12]. However, when MsRbpA was further added 59 after the addition of rifampicin or 109 after the total reaction time, RNA products started reappearing again [ Fig. 3(c) , lanes 5-8]. As expected, MsRbpA stimulated multiple round of transcription in the absence of rifampicin [ Fig. 3(c) , iv]. Quantitative estimation of the scheme of the reaction is shown in Fig. 3(d) .
To investigate whether MtbRbpA is capable of rescuing transcription from the inhibitory effect of rifampicin like MsRbpA, we carried out single round transcription reactions on the P rrnAPCL1 promoter using M. smegmatis holo RNAP in the presence of rifampicin. We found that MtbRbpA can rescue transcription from the inhibitory effect of rifampicin even at 100 mM concentration (Fig. 4a,  b) . Furthermore, there was a concomitant increase in the level of transcription with increasing concentration of MtbRbpA (Fig. 4c, d ). However, another group was not able to detect this rescue activity of MtbRbpA through their abortive initiation assays and they showed that in the presence of MtbRbpA there was only an~twofold increase in abortive product formation (Hu et al., 2012) .
The sequence Asn 58 to Lys 73 is required for the function of MsRbpA
In a previous report (Dey et al., 2011) we showed that a 16 aa peptide fragment of MsRbpA from Asn 58 to Lys 73 (NGLEGTLIEGDVPEPK) of MsRbpA cross-linked to Transcription intensity Transcription intensity Fig. 4 . Effect of MtbRbpA on single round promoter-specific transcription in the presence and absence of rifampicin. The arrow shows 10 % urea-PAGE 120 nt run-off transcripts illustrating the effect of MtbRbpA on single round transcription reaction in the presence and absence of rifampicin on P rrnAPCL1 with RNAP (a, c). RNAP was incubated with rifampicin for 5 min, MtbRbpA was added and further incubated for 10 min, P rrnAPCL1 promoter was added and incubation was carried out for another 10 min. After the addition of NTP-heparin mixture transcription was allowed to proceed for 5 min and the reaction was stopped. The band intensities of the transcripts from duplicate reactions of (a) and (c) were quantified and plotted in (b) and (d), respectively. RNAP, P rrnAPCL1 , rifampicin and MtbRbpA added to the reaction as labelled in the figure. ", Absence of the component; +, presence of the component.
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Arg 381 of the b-subunit of RNAP. We were interested to elucidate the significance of this peptide fragment in the function of MsRbpA. We deleted the entire 16 aa stretch from MsRbpA to form MsRbpA D58-73 (Fig. 5a ). Circular dichroism (Fig. S5 ) and size exclusion chromatography (Fig. S6 ) of MsRbpA D58-73 suggested that its conformation was not very different from that of the wild-type protein.
Next, we carried out single round transcription on the P rrnAPCL1 promoter as described earlier and found that it was deficient in both transcription activation [ Fig. 5(b) and (c), lane 3] and rescue activity [ Fig. 5(b) and (c) To identify functional residues among Asn 58 to Lys 73 through alanine scanning, each individual residue was converted into alanine. With these alanine mutants of MsRbpA, single round transcription at the P rrnAPCL1 promoter was carried out to check for their ability to activate transcription (Fig. 6a) and to rescue rifampicininduced transcription inhibition (Fig. 6b) . We observed that G67A, V69A, P70A and P72A mutants (Fig. 6c ) lost close to 50 % activity in terms of both transcriptional activation and rescue, suggesting the importance of these residues for MsRbpA function. These four residues are part of an unstructured loop just after the fourth b-strand of the molecule (Fig. 6d) . These four amino acid residues are also found to be conserved in MtbRbpA (Fig. 6e) . Additionally, we observed a higher shift in the mobility of the transcripts where an acidic residue has been mutated to alanine (E61A, E66A, D68A and E71A). We have not addressed the reason for this shift.
MsRbpA is an essential protein for M. smegmatis
Our initial attempts to delete MsRbpA from the M. smegmatis chromosome were unsuccessful, which suggested that MsRbpA is perhaps essential for the viability of M. smegmatis. We constructed a strain (MS 101) that allows conditional depletion of MsRbpA upon addition of ATc. In the absence of ATc, TetR represses transcription of Pip, and therefore it cannot repress transcription of MsRbpA. When ATc is present, it binds to TetR and makes it unavailable for repression of transcription of Pip, and thus it is expressed and represses the transcription of MsRbpA. In the presence of 800 ng ATc ml
21
, where MsRbpA has been completely knocked down, the strain becomes non-viable, indicating MsRbpA is indispensable for the survival of M. smegmatis (Fig. 7) .
DISCUSSION
We show here that MsRbpA enhances RPc formation and increases the rate of conversion to the stable RP. This explains how MsRbpA stimulates the formation of stable RNAPpromoter complex as reported previously (Hu et al., 2012) . The effect of MsRbpA during transcription ensues prior to the formation of the stable RNAP-promoter complex. Bortoluzzi et al. (2013) . The region coloured in red corresponds to the 16 aa deleted fragment of MsRbpA. (b) 10 % Urea-PAGE showing 120 nt run-off transcripts in single round transcription assays performed using RNAP (100 nM), P rrnAPCL1 (10 nM) without rifampicin (lanes 1-3) or with rifampicin (10 mM) (lanes 4-6): with MsRbpA (2.5 mM) (lanes 2 and 5); with MsRbpA D58-73 (2.5 mM) (lanes 3 and 6). RNAP was incubated with rifampicin for 5 min, MsRbpA/MsRbpA D58-73 was added and further incubated for 10 min, P rrnAPCL1 promoter was added and incubation was carried out for another 10 min. After the addition of NTP-heparin mixture transcription was allowed to proceed for 5 min and the reaction was stopped.
Here, we have studied the effect of MsRbpA on both single and multiple round transcriptions in the presence and absence of rifampicin. This was necessary to check whether the rescue phenomenon observed is due to the transcription activation property of MsRbpA. The results shown reassert the previous finding (Dey et al., 2010 (Dey et al., , 2011 MsRbpA is able to rescue transcription from the state of transcription arrest induced by rifampicin or is able to activate transcription even in the presence of rifampicin. It is well known that rifampicin does not prevent RPc or RPo formation (Hinkle et al., 1972; McClure & Cech, 1978) , but rather inhibits the transcription by blocking the formation Each of the alanine mutants is indicated above its respective lane. RNAP was incubated with rifampicin for 5 min, MsRbpA/ MsRbpA mutants were added and further incubated for 10 min, P rrnAPCL1 promoter was added and incubation was carried out for another 10 min. After the addition of NTP-heparin mixture transcription was allowed to proceed for 5 min and the reaction was stopped. The mean value of three replicates of the transcription band intensities corresponding to (a) and (b) were plotted in (c) as a fractional change after normalizing with the band intensity obtained in the presence of WT MsRbpA. The four important amino acid residues are marked on the solution structure of M. tuberculosis RbpA (d). Comparisons of the deleted 16 aa residues of MsRbpA (MSMEG_3858) with its M. tuberculosis counterpart (Rv2050). The important amino acids of this region are marked with an asterisk above them (e).
A. K. Verma and D. Chatterji of RNA beyond 2-3 nt. However, full-length transcripts are formed even in the presence of rifampicin and MsRbpA. This suggests that rifampicin needs to be dissociated from the RNA exit channel of RNAP to allow transcription to proceed. This hypothesis has been tested through fluorescence quenching experiments (Dey et al., 2011) . The plausible explanation for the rescue effect of MsRbpA appears to be that in the presence of MsRbpA, a rifampicin molecule is released from the rifampicin binding pocket of RNAP. As a result, the RNAP molecule devoid of rifampicin is further acted upon by MsRbpA, enhancing RPc formation and increasing the rate of RP formation. This in turn leads to the increased production of full-length transcripts. MsRbpA is capable of rescuing transcription independent of the order of addition of rifampicin or MsRbpA, suggesting that in the presence of MsRbpA, rifampicin is not able to block the path of the RNA exit channel. However, the binding of rifampicin to its pocket is very tight (Dey et al., 2011) and thus it is difficult to envisage how the antibiotic is ejected out from its niche. It seems that binding of MsRbpA results in a change in the conformation of RNA exit channel in the enzyme, but we have no experimental evidence in support of this hypothesis. Hu et al. (2012) reported that MtbRbpA does not rescue the abortive initiation of transcription at the rrnAP3 promoter from M. tuberculosis, when inhibited by rifampicin. However, we have cloned and purified MtbRbpA and subsequently monitored single round transcription at the P rrnAPCL1 promoter from M. smegmatis, catalysed by M. smegmatis RNAP in the presence of rifampicin; the protein was capable of rescuing rifampicin-induced transcription inhibition. The primary sequences of M. smegmatis and M. tuberculosis RNAP are similar (Table S3 ). This led us to believe that there is a high level of homology between the tertiary structures of the enzymes. We also observed that for M. smegmatis RNAP reconstituted from different subunits obtained from both M. smegmatis and M. tuberculosis, the heterologous enzyme behaves similar to purified M. smegmatis RNAP. However, it is likely that the activation or rescue effect of MsRbpA is dependent on the nature of the promoter used in the transcription assays. The role of the s factor in the function of RbpA has been reported earlier. The C terminus of ScRbpA (RbpA from S. coelicolor) is required for the interaction with s domain 2 of the principal s factor (s HrdB ). It was proposed that ScRbpA appears to influence s cycling in actinobacteria (Tabib-Salazar et al., 2013) . Another study (Bortoluzzi et al., 2013) showed that N and C termini of MtbRbpA (RbpA from M. tuberculosis) interact with the N terminus of s B , whereas the C terminus of MtbRbpA is required for the its oligomerization. Both of these groups focused on the N and C termini of RbpA in the context of their interaction with the s factor. Our study, however, focuses on the region of MsRbpA, which is neither involved in the binding of the s factor nor interferes with the process of oligomerization. Nonetheless, this region of MsRbpA (Fig. 5a ) was shown to bind to the b subunit of RNAP (Dey et al., 2011) . MsRbpA D58-73 is inactive in terms of both transcription activation and transcription rescue. It also interacts with core RNAP with 1000-fold less affinity, although it retains its s A binding property, suggesting that the MsRbpA-core RNAP interaction is critical with respect to its functions. It is intriguing that MsRbpA and M. smegmatis RNAP have undergone co-evolution (Dey et al., 2012) . Thus, it can be hypothesized that the range of environmental onslaughts a bacterium faces to survive might have triggered the synthesis of this protein to counter the effect, at least in part.
We found that mutating Gly 67, Val 69, Pro 70 and Pro 72 of MsRbpA into alanine results in an~50 % reduction in their activation as well as rescue function. We propose that these four amino acids are important for MsRbpA functions. These residues are a part of an unstructured loop immediately after the fourth b strand of the molecule. We speculate that even if one residue is mutated, other residues in the vicinity of that region allow it to interact with the b subunit, resulting in only partial reduction in its function. Another important observation that has emerged is that these mutants are defective in both functions, i.e. activation and rescue, suggesting that these two phenomena are coupled.
RbpA from S. coelicolor was shown to be dispensable for the bacteria (Newell et al., 2006) , whereas it is essential for M. tuberculosis (Forti et al., 2011) . Here we have shown that RbpA from M. smegmatis is essential for viability. Although all these bacteria belong to the same family of actinomycetes, from an evolutionary and structural point of view we find that RbpA from M. smegmatis is more similar to the RbpA from M. tuberculosis than that of S. coelicolor.
The interaction of RbpA with the b subunit of RNAP in addition to s A may be useful to target mycobacteria, as the protein is essential for survival.
